Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum (Q71767084)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference

1 reference

J B Burruss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

E R Farmer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

J P Callen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

language of work or name

English

0 references

publication date

1 November 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American Academy of Dermatology

21 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

5 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

720-724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

Treatment of pyoderma gangrenosum with cyclosporine

21 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Pyoderma gangrenosum; a clinical study of nineteen cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Diaminodiphenylsulfone and steroids in the treatment of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Bilateral pyoderma gangrenosum of the hand: treatment with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Clofazimine. A new agent for the treatment of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Efficacy of human intravenous immune globulin in pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Chlorambucil--an effective corticosteroid-sparing therapy for pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Successful treatment of aggressive pyoderma gangrenosum with pulse steroids and chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Chlorambucil in the treatment of patients with immune-mediated rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

Malignancies induced by chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990727-6

7 January 2021

10.1016/S0190-9622(96)90727-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8912567%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference